STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: In a current study, Patel et al. showed that STAT3 in CML stem and progenitor cells regulated the development of resistance to tyrosine kinase inhibitors by metabolic programming, and metabolism in TKI-persistent leukemic cells was reported to be in a glycolytic state unless inhibition of STAT3 using a small molecule inhibitor.